Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient.

Abstract	[This corrects the article DOI: 10.3389/fonc.2022.929763.].
Authors	Sha-Sha Wang, Fang Wang, Zhen Zeng, Fang Gao, Huan-Huan Liu, Hui-Na Wang, Yi Hu, Hai-Feng Qin
Journal	Frontiers in oncology (Front Oncol) Vol. 12 Pg. 1113289 ( 2022) ISSN: 2234-943X [Print] Switzerland
PMID	36582807 (Publication Type: Published Erratum)
Copyright	Copyright © 2022 Wang, Wang, Zeng, Gao, Liu, Wang, Hu and Qin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!